Matthew C. Hill
Matthew C. Hill's purchase track record
How the stock did after each of Matthew C. Hill's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/13/2024 | APYX | $6K | +24.6% | +27.3% | +11.7% |
| 12/12/2023 | APYX | $5K | -21.1% | -29.4% | +15.8% |
| 12/13/2021 | PDSB | $28K | -43.9% | -66.3% | -19.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
No recent news for PDSB in the past week. PDSB has not issued any new corporate announcements or earnings releases in the last seven days. The stock is trading near its 52‑week low, with an RSI of 59.5 and a support level at $0.21. Analysts maintain an average target of $4.75, while the 52‑week range spans $0.20 to $1.55. No significant events have impacted the company’s outlook recently.
Transaction History
| APYX | ▲ Buy | Open Market | 5,336 | $6K | 8/13/2024 | View on chart |
| APYX | ▲ Buy | Open Market | 2,500 | $5K | 12/12/2023 | View on chart |
| PDSB | ▲ Buy | Open Market | 2,500 | $23K | 12/13/2021 | View on chart |
| PDSB | ▲ Buy | Open Market | 400 | $4K | 12/13/2021 | View on chart |
| PDSB | ▲ Buy | Open Market | 100 | $900 | 12/13/2021 | View on chart |
| PDSB | ▲ Buy | Open Market | 100 | $900 | 12/13/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Apyx Medical featured in cold plasma market growth report
Apyx Medical was named as a key player in a new report projecting the cold plasma market to grow from $3.32 billion in 2025 to $8.45 billion by 2032. This industry-level forecast highlights the long-term potential of the sector in which Apyx operates. The company's stock is currently trading below its average analyst target price, reflecting ongoing market uncertainty despite these broader industry trends.
Apyx Medical featured in cold plasma market growth report. Apyx Medical was named as a key player in a new report projecting the cold plasma market to grow from $3.32 billion in 2025 to $8.45 billion by 2032. This industry-level forecast highlights the long-term potential of the sector in which Apyx operates. The company's stock is currently trading below its average analyst target price, reflecting ongoing market uncertainty despite these broader industry trends.